LAA (Left Atrial Appendage) closure

This major late-breaking trial from EuroPCR 2026 highlights new insights from the CHAMPION AF study, one of the largest randomised trials comparing left atrial appendage closure (LAAC) with direct oral anticoagulants (DOACs) in patients with atrial fibrillation. In this interview, Philippe Garot and Jens Erik Nielsen-Kudsk...

This session explores the transformative role of advanced imaging, particularly 3D intracardiac echocardiography (ICE), in modern structural heart interventions. It provides practical insights into implementation, highlighting how these tools can enhance workflow efficiency and procedural confidence across transcatheter edge-to-edge repair (TEER), left atrial appendage (LAA) closure,...

These trials were selected for their design, results, and potential to impact clinical practice: discover the key findings of an IPD meta-analysis on coronary revascularisation in TAVI patients, a long-term comparison of PCI vs. CABG for left main disease, and a study on LAA closure vs....

This session reviews the latest CHAMPION AF trial data and its implications for left atrial appendage (LAA) closure in patients with atrial fibrillation.

It explores how emerging evidence may influence clinical practice and patient selection, and how LAA closure could evolve across different atrial fibrillation populations. 

A recorded...

Paris, France, 19−22 May 2026. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during EuroPCR 2026 and are set to impact practice worldwide. Among them is a subgroup analysis of the CHAMPION-AF trial investigating stroke-prevention strategies...

The study aimed to evaluate the impact of LAAC device implantation depth on local flow characteristics and its association with device-related thrombus using patient-specific computational fluid dynamics.

In this replay, P. Garot, M. Bergmann and J.E. Nielsen‑Kudsk review current indications for LAAC, insights from the CHAMPION‑AF trial and practical case learnings.

During the first Late-Breaking Trial session of the 2026 ACC Congress held in New Orleans, Saibal Kar, principal investigator of the CHAMPION-AF trial, presented the 3-year results of this groundbreaking study, which were simultaneously published in the NEJM (DOI: 10.1056/NEJMoa2517213).

Catheter-based left atrial appendage closure (LAAC) is widely used as an alternative to oral anticoagulation in atrial fibrillation. But how does it compare with best medical therapy in patients at high risk of both stroke and bleeding? The CLOSURE-AF trial provides new data to inform this...

This session delves into the advances in stroke prevention for patients undergoing TAVI with atrial fibrillation, focusing on left atrial appendage closure (LAAC) and cerebral protection strategies. It highlights the evolving role of WATCHMAN devices and the SENTINEL Cerebral Protection System, emphasising perioperative stroke risk management...